257 related articles for article (PubMed ID: 30791148)
1. CRTAM
Ramírez-Ramírez D; Padilla-Castañeda S; Galán-Enríquez CS; Vadillo E; Prieto-Chávez JL; Jiménez-Hernández E; Vilchis-Ordóñez A; Sandoval A; Balandrán JC; Pérez-Tapia SM; Ortiz-Navarrete V; Pelayo R
J Leukoc Biol; 2019 May; 105(5):999-1013. PubMed ID: 30791148
[TBL] [Abstract][Full Text] [Related]
2. Acute lymphoblastic leukemia of NK-cell lineage: responses to IL-2.
Pirruccello SJ; Bicak MS; Gordon BG; Gajl-Peczalska K; Gnarra DJ; Coccia PF
Leuk Res; 1989; 13(9):735-43. PubMed ID: 2796381
[TBL] [Abstract][Full Text] [Related]
3. The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM.
Boles KS; Barchet W; Diacovo T; Cella M; Colonna M
Blood; 2005 Aug; 106(3):779-86. PubMed ID: 15811952
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells adhere to bone marrow fibroblasts and inhibit adhesion of acute myeloid leukemia cells.
Bendall LJ; Kortlepel K; Bradstock KF; Gottlieb DJ
Leukemia; 1995 Jun; 9(6):999-1005. PubMed ID: 7596192
[TBL] [Abstract][Full Text] [Related]
5. Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells.
Arase N; Takeuchi A; Unno M; Hirano S; Yokosuka T; Arase H; Saito T
Int Immunol; 2005 Sep; 17(9):1227-37. PubMed ID: 16091383
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells derived from low risk acute lymphoblastic leukemia patients promote NK cell antitumor activity.
Entrena A; Varas A; Vázquez M; Melen GJ; Fernández-Sevilla LM; García-Castro J; Ramírez M; Zapata AG; Vicente Á
Cancer Lett; 2015 Jul; 363(2):156-65. PubMed ID: 25917077
[TBL] [Abstract][Full Text] [Related]
7. T-cell receptor gamma/delta expressing acute leukemia emerging from sideroblastic anemia: morphological, immunological, and cytogenetic features.
Meckenstock G; Fonatsch C; Heyll A; Schneider EM; Kögler G; Söhngen D; Aul C; Schneider W
Leuk Res; 1992; 16(4):379-84. PubMed ID: 1373459
[TBL] [Abstract][Full Text] [Related]
8. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
9. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
10. Human natural killer cell development from bone marrow progenitors: analysis of phenotype, cytotoxicity and growth.
Lotzová E; Savary CA
Nat Immun; 1993; 12(4-5):209-17. PubMed ID: 8257827
[TBL] [Abstract][Full Text] [Related]
11. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia.
Suzuki R; Nakamura S
Leuk Res; 1999 Jul; 23(7):615-24. PubMed ID: 10400182
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of NK cells in Mexican pediatric patients with acute lymphoblastic leukemia: Report from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia.
Valenzuela-Vazquez L; Núñez-Enríquez JC; Sánchez-Herrera J; Jiménez-Hernández E; Martín-Trejo JA; Espinoza-Hernández LE; Medina-Sanson A; Flores-Villegas LV; Peñaloza-González JG; Refugio Torres-Nava J; Espinosa-Elizondo RM; Amador-Sánchez R; Santillán-Juárez JD; Flores-Lujano J; Pérez-Saldívar ML; García-López LR; Castañeda-Echevarría A; Rodríguez-Leyva F; Rosas-Vargas H; Mata-Rocha M; Duarte-Rodríguez DA; Sepúlveda-Robles OA; Mancilla-Herrera I; Mejía-Aranguré JM; Cruz-Munoz ME
PLoS One; 2020; 15(1):e0227314. PubMed ID: 31951638
[TBL] [Abstract][Full Text] [Related]
13. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies.
Yamada O; Ichikawa M; Okamoto T; Park C; Motoji T; Mizoguchi H; Shibuya A
Br J Haematol; 2001 Apr; 113(1):153-60. PubMed ID: 11328295
[TBL] [Abstract][Full Text] [Related]
14. Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL.
Balandrán JC; Dávila-Velderrain J; Sandoval-Cabrera A; Zamora-Herrera G; Terán-Cerqueda V; García-Stivalet LA; Limón-Flores JA; Armenta-Castro E; Rodríguez-Martínez A; Leon-Chavez BA; Vallejo-Ruiz V; Hassane DC; Pérez-Tapia SM; Ortiz-Navarrete V; Guzman ML; Pelayo R
Front Immunol; 2021; 12():746492. PubMed ID: 34737747
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
Peragine N; Torelli GF; Mariglia P; Pauselli S; Vitale A; Guarini A; Foà R
Cancer Immunol Immunother; 2015 Feb; 64(2):201-11. PubMed ID: 25341808
[TBL] [Abstract][Full Text] [Related]
16. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
17. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
[TBL] [Abstract][Full Text] [Related]
19. Leukemic priming of resting NK cells is killer Ig-like receptor independent but requires CD15-mediated CD2 ligation and natural cytotoxicity receptors.
Sabry M; Tsirogianni M; Bakhsh IA; North J; Sivakumaran J; Giannopoulos K; Anderson R; Mackinnon S; Lowdell MW
J Immunol; 2011 Dec; 187(12):6227-34. PubMed ID: 22084431
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
